yep, I saw that. I am sure when Gilead put down $4.9b they knew this end result was possible. I wonder what bisantrene's historical clinical data is worth to a potential buyer/license partner in terms of reducing a similar risk.
Speculative M&A Transaction Analysis, page-799
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
0.025(1.64%) |
Mkt cap ! $264.2M | |||
| Open | High | Low | Value | Volume |
| $1.53 | $1.58 | $1.53 | $6.491K | 4.21K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16341 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.55 | 200 | 1 |
View Market Depth
| Last trade - 10.43am 12/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |